Loading asset research
SCYNEXIS Inc. Common Stock
SCYXNasdaq · USD · StocksQuote as of · Exchange session not verified$4.84
+2.98%
Today
SCYX
Loading 1D prices…
Market cap
$48.2M
Volume
30.4K
52w high
$9.5252w low
$3.53Company profile
SCYNEXIS Inc. Common Stock
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Jersey City, NJ, United States
Employees
18
Fiscal year end
1231
CIK
1178253
Session & valuation
Open$4.72
Previous close$4.70
Day high$5.06
Day low$4.72
30-day avg. volume196.4K
Outstanding shares9.9M
Diluted EPS-$0.17
Latest annual period
P/E (trailing)-28.47
P/E (forward)-2.09
Price / book0.72
Beta1.11
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| HOWLWerewolf Therapeutics Inc. Common Stock | $47.7M | $0.00 | — | -$1.33 | -0.82% | Buy |
| ANVSAnnovis Bio Inc. Common Stock | $47.7M | $0.00 | — | -$1.40 | -5.88% | Buy |
| IBOImpact BioMedical Inc. Common Stock | $49.6M | $32K | -36993.75% | -$0.38 | +4.31% | Unrated |
| GRCEGrace Therapeutics Inc. Common Stock | $46.7M | $0.00 | — | -$0.47 | -1.77% | Buy |
| MCRBSeres Therapeutics Inc. Common Stock | $50.3M | $789K | +721.93% | $0.64 | -1.76% | Buy |